In the article entitled, “The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans” (Volume 190, pages 1397–1413 of the July 2020 issue of The American Journal of Pathology; https://doi.org/10.1016/j.ajpath.2020.03.011), there was a copyediting error in the use of tafazzin and the expansion of TAZ. TAZ is the official gene symbol for tafazzin (transcriptional coactivator with PDZ-binding motif) however it is also an alias for WW Domain Containing Transcription Regulator 1 (WWTR1). These are two different genes, and this was expanded incorrectly during copyediting. Tafazzin (TAZ) does not belong to the Hippo pathway. TAZ in this manuscript should be defined as “WW Domain Containing Transcription Regulator 1 (WWTR1)” at all locations. The title of this manuscript should also update to read: The Hippo Effector WW Domain Containing Transcription Regulator 1 (WWTR1) Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans”.
This was correct in the manuscript as submitted and accepted, and was incorrectly updated during the proof process. All of the results contained in the manuscript remain valid in relation to WW Domain Containing Transcription Regulator 1 (WWTR1).